和铂医药-B与 AstraZeneca修订合作协议 合作范围进一步扩展

Core Viewpoint - The collaboration between Heptagon Pharmaceuticals and AstraZeneca aims to leverage both companies' expertise to discover and develop next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers [1] Group 1: Collaboration Details - Heptagon Pharmaceuticals' indirect wholly-owned subsidiary, Heptagon (Shanghai) Co., Ltd., has entered into a collaboration, option, and licensing agreement with AstraZeneca [1] - The scope of cooperation has been further expanded following the revised collaboration agreement signed on November 24, 2025 [1] - The financial framework established under the collaboration agreement remains consistent with previous terms [1]